查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1931218

伽玛束立体定位放射治疗系统市场（按组件、应用和最终用户划分），全球预测（2026-2032）

Gamma Beam Stereotactic Radiotherapy System Market by Component, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年，伽玛束立体定位放射治疗系统市场价值为 1.5902 亿美元，预计到 2026 年将成长至 1.7425 亿美元，预计到 2032 年将达到 2.6667 亿美元，复合年增长率为 7.66%。

关键市场统计数据
基准年 2025 1.5902亿美元
预计年份：2026年 1.7425亿美元
预测年份 2032 2.6667亿美元
复合年增长率 (%) 7.66%

权威概述聚焦于颅内放射治疗平台，重点在于针对复杂神经系统疾病的精准治疗、影像整合和临床工作流程协调。

伽玛束立体定位放射治疗系统是一类独特的精准治疗平台，旨在将聚焦辐射精准输送至颅内标靶区，同时保护周围正常组织。这些系统结合了精密的束流准直、亚毫米级的患者定位精度和先进的影像引导技术，可实现单次或低分割治疗方法，尤其适用于复杂的颅内病变。临床医生越来越重视整合了强大的影像模式、自适应治疗计划和简化的工作流程的系统，以支援快速且可重复的治疗实施。

整合型成像、先进准直、人工智慧驱动的治疗计划以及一体化服务模式正在重新定义放射外科中心的治疗精度和临床工作流程。

立体定位放射外科的格局正在迅速变化，这主要得益于技术融合、不断累积的临床证据以及不断发展的治疗模式。影像融合技术的进步，特别是CT和MRI资料集在计画和术中引导中的整合，提高了靶区勾画的精确度，并实现了对关键结构周围更严格的安全边界。同时，准直器技术的改进，包括更灵活的扇形设计，在维持或提高剂量适形性的同时，增强了治疗的柔软性，并提高了单次放射放射线手术转移性疾病和某些功能性疾病的可行性。

评估 2025 年关税趋势如何改变医疗设备采购、服务合约和资本财筹资策略，加速供应链韧性措施。

美国2025年生效的关税政策为资本密集医疗设备供应商及其采购者—医疗系统—带来了额外的成本和供应链的不确定性。最直接的影响体现在零件采购决策上，尤其是那些依赖特殊製造製程和进口零件的子系统，例如准直器机构和成像硬体。因此，采购团队和供应商开始重新评估供应商合同，加快双源采购策略的实施，并权衡短期价格调整和长期供应商整合之间的利弊，以确保关键零件的供应和设备的运作。

将临床适应症、临床环境、硬体和软体权衡以及端到端服务需求与临床结果和采购优先事项联繫起来的细分市场分析

细緻的细分观点能够清楚展现临床价值与商业性机会在应用、终端使用者、组件和服务层面的交会点。应用层级的差异化至关重要，因为动静脉畸形需要高精度的放射外科局部照射，脑肿瘤需要与手术和全身治疗协调的多模态治疗计划，脑转移瘤需要快速週转和单次或低分割照射计划，而三叉神经痛则需要功能性靶向治疗并最大限度地减少副作用。这些临床差异会影响设备配置的选择和临床工作流程的设计。

临床应用、报销驱动因素和基础设施投资的区域差异，正在塑造美洲、欧洲、中东和非洲以及亚太地区的差异化应用策略。

区域趋势影响立体定位放射手术的技术采纳、报销途径以及临床网路结构。在美洲，成熟的研究型医院体系、认可立体定位放射放射线手术疗效的支付方报销模式以及强劲的资本市场，都为早期采用整合影像和软体主导平台提供了支援。主要都会地区的卓越医疗中心作为转诊和培训中心，制定了其他医疗机构效仿的临床通讯协定。同时，在适当的临床管治下，门诊机构也越来越多地参与特定手术的实施。

竞争优势源自于整合的临床证据、模组化的软硬体平台、社区服务网路以及能够满足医疗服务提供者不断变化的需求的灵活商业模式。

在该领域，竞争优势将越来越取决于企业如何平衡产品差异化、临床证据产生和服务品质。将模组化硬体与先进治疗计画平台结合的主要企业，能够缩短整个治疗流程的时间，并拓展临床适应症范围，从而提供极具吸引力的价值提案。与学术机构和研究型医院进行策略合作，可以加速临床检验，并为指南采纳铺平道路；而与影像设备供应商建立伙伴关係，则有助于更紧密地整合治疗计划和术中影像技术。

为技术提供者和医疗系统提供切实可行的策略和营运措施，以加速安全应用、优化生命週期经济效益并维持临床疗效

产业领导者必须采取切实可行的措施，确保营运的永续性，同时赢得临床信任。投资于支援CT和MRI规划工作流程的整合成像相容性，并提供模组化准直器选项，将扩大临床应用范围，并减少机构层面的客製化需求。同样重要的是，优先改进软体，以实现常规规划任务的自动化，加快品质保证流程，并向多学科团队呈现具有临床意义的规划权衡方案。此外，与学术和研究机构正式合作，共同製定通讯协定并发表研究成果，将有助于支付者和指南制定决策。

采用混合调查方法，结合临床医师访谈、技术规范审核、法规审查和供应链分析，以获得可靠且可操作的见解。

本分析整合了原始定性资料和二手技术审查，以确保实证的严谨性和临床相关性。原始研究包括对放射肿瘤科医生、神经外科医生、医学物理学家、医院采购经理和服务工程师进行结构化访谈，以了解临床、技术和财务决策标准。二手研究回顾了同行评审的临床文献、医疗设备监管文件、诊断影像和剂量学技术报告以及已发布的医院采购框架，以检验技术声明和服务模式。

整合临床、技术和营运方面的优先事项，突显决定持续应用和持续临床影响的关键因素

整体评估发现，技术能力、服务成熟度和营运韧性已趋于整合，这预示着将决定长期成功的关键转折点。在临床方面，该系统能够提供精确的剂量测定、整合成像和简化的治疗计划，满足神经外科和放射肿瘤科团队治疗动静脉畸形、原发性和转移性脑瘤以及三叉神经痛等功能性疾病的核心需求。在商业方面，该系统能够提供永续的服务协议、模组化硬体选项以及可加速吞吐量的软体平台，从而为从学术机构到门诊手术中心等各类终端用户创造极具吸引力的价值提案。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 伽玛束立体定位放射治疗系统市场（按组件划分）

  • 硬体
    • 准直器系统
      • 固定准直器
      • 扇形准直器
    • 影像系统
      • 基于CT的影像
      • 基于磁振造影的成像
    • 病人定位系统
  • 软体
    • 辐射控制系统
    • 治疗计划平台
  • 服务
    • 安装和试运行
    • 预防性维护
    • 培训和支持

9. 伽玛束立体定位放射治疗系统市场（依应用划分）

  • 动静脉畸形
  • 脑肿瘤
  • 转移性脑病变
  • 三叉神经痛

10. 伽玛束立体定位放射治疗系统市场（以最终用户划分）

  • 学术研究机构
  • 门诊手术中心
  • 癌症研究所
  • 医院

11. 各地区伽玛束立体定位放射治疗系统市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十二章 伽玛束立体定位放射治疗系统市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

13. 各国伽玛束立体定位放射治疗系统市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

14. 美国伽玛束立体定位放射治疗系统市场

第十五章 中国伽玛束立体定位放射治疗系统市场

第十六章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Accuray Incorporated
  • Brainlab AG
  • C-Rad AB
  • Canon Medical Systems Corporation
  • Elekta AB
  • GE Healthcare
  • Hitachi, Ltd.
  • IBA Worldwide
  • LinaTech LLC
  • Mevion Medical Systems, Inc.
  • Mitsubishi Electric Corporation
  • Neusoft Medical Systems Co., Ltd.
  • Philips Healthcare
  • ProTom International, Inc.
  • RaySearch Laboratories AB
  • Shenzhen Anke High-tech Co., Ltd.
  • Shinva Medical Instrument Co., Ltd.
  • Sumitomo Heavy Industries, Ltd.
  • TopGrade HealthCare Inc.
  • Toshiba Corporation
  • United Imaging Healthcare Co., Ltd.
  • Varian Medical Systems, Inc.
  • ViewRay, Inc.
  • Wandong Medical Equipment Co., Ltd.
Product Code: MRR-7B550E008DC6

The Gamma Beam Stereotactic Radiotherapy System Market was valued at USD 159.02 million in 2025 and is projected to grow to USD 174.25 million in 2026, with a CAGR of 7.66%, reaching USD 266.67 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 159.02 million
Estimated Year [2026] USD 174.25 million
Forecast Year [2032] USD 266.67 million
CAGR (%) 7.66%

An authoritative overview of focused intracranial radiosurgery platforms emphasizing precision delivery, imaging integration and clinical workflow alignment for complex neurological indications

Gamma beam stereotactic radiotherapy systems represent a distinct class of high-precision therapeutic platforms designed to deliver focused radiation to intracranial targets while sparing surrounding healthy tissue. These systems combine refined beam collimation, submillimeter patient positioning accuracy, and advanced imaging guidance to enable single-session and hypofractionated treatment regimens that are particularly well suited for complex intracranial pathologies. Clinicians increasingly prioritize systems that integrate robust imaging modalities, adaptive treatment planning, and streamlined workflows to support fast, reproducible care delivery.

Clinical indications for this technology span arteriovenous malformation, primary and secondary brain tumors, metastatic brain disease, and functional targets such as trigeminal neuralgia. End users for these systems include academic and research institutes driving clinical innovation, hospitals providing high-volume neurosurgical and radiation oncology services, ambulatory surgical centers adapting to outpatient procedural models, and dedicated cancer research institutes pursuing translational studies. As hospitals and specialty centers evaluate these platforms, decision criteria center on dosimetric accuracy, imaging compatibility, service and training support, and the ability to integrate into multi-disciplinary care pathways that include neurosurgery, neuro-oncology, and radiation physics.

How convergent imaging, advanced collimation, AI-enabled treatment planning and integrated service models are redefining therapeutic precision and clinical workflows across radiosurgery centers

The landscape for stereotactic radiotherapy is shifting rapidly under the influence of technological convergence, clinical evidence expansion, and evolving care models. Advances in imaging integration-particularly the blending of CT and MRI datasets into planning and intra-procedural guidance-have raised the bar for target delineation and enabled tighter margins around critical structures. Concurrently, improvements in collimator technology, including more versatile sectorized designs, have increased treatment flexibility while preserving or enhancing dose conformity, making single-session radiosurgery for metastatic disease and select functional disorders more feasible.

Software-driven innovation likewise drives change: treatment planning platforms with faster optimization engines, automation for contouring and plan generation, and the early incorporation of machine learning to predict dosimetric trade-offs shorten time from referral to treatment. Service models are also transforming; providers expect not only installation and commissioning but ongoing preventive maintenance, rapid corrective responses, and comprehensive training programs that embed competency in multidisciplinary teams. These shifts coalesce around a central theme: systems that offer end-to-end clinical and operational integration, from imaging through delivery and post-treatment follow-up, will define competitive differentiation.

Assessing how 2025 tariff dynamics altered component sourcing, service contracts and procurement strategies for capital medical devices and drove accelerated supply-chain resilience measures

United States tariff actions in 2025 introduced a layer of cost and supply-chain uncertainty for capital-intensive medical equipment suppliers and health systems procuring them. The immediate effects were visible in component sourcing decisions, particularly for subsystems such as collimator mechanisms and imaging hardware that rely on specialized manufacturing and imported parts. As a consequence, procurement teams and vendors began reevaluating supplier contracts, accelerating dual-sourcing strategies, and examining the trade-offs between short-term price adjustments and long-term supplier consolidation to secure critical parts and sustain uptime commitments.

Beyond direct input cost pressure, tariffs influenced strategic decisions around local assembly, service footprint expansion, and inventory policies. Some manufacturers prioritized increased domestic content in high-risk components to shield pricing from further tariff volatility, while others offered extended service plans and consumable bundling to smooth lifecycle costs for end users. Health systems responded by intensifying total-cost-of-ownership analyses that place heavier emphasis on service reliability, spare-part availability, and training that reduces corrective maintenance incidence. In sum, tariff-driven dynamics pushed both suppliers and purchasers toward resilience measures that emphasize supply-chain transparency, maintenance-first commercial propositions, and modular system architectures that can better tolerate component substitution without degrading clinical performance.

Segment-level analysis linking clinical indication, care setting, hardware and software trade-offs and end-to-end service requirements to clinical outcomes and procurement priorities

A nuanced segmentation view clarifies where clinical value and commercial opportunity intersect across applications, end users, components and services. Application-level differentiation matters because arteriovenous malformations demand extreme precision and radiosurgical nidus coverage, brain tumors require multimodal planning with potential surgery or systemic therapy coordination, metastatic brain disease often benefits from rapid throughput and single- or few-fraction regimens, and trigeminal neuralgia emphasizes functional targeting and secondary effects minimization. These clinical distinctions shape both device configuration choices and clinical workflow design.

End-user segmentation further refines requirements: academic and research institutes prioritize extensibility for protocol-driven innovation and robust data capture, hospitals require streamlined interoperability with existing imaging and oncology information systems, ambulatory surgical centers emphasize compact footprints and fast turnover, and cancer research institutes focus on integration with trial infrastructure. Component segmentation underscores the technical trade-offs between hardware and software investments. Hardware choices span the collimator system with options such as fixed versus sector collimators, imaging systems ranging from CT-based to MRI-based architectures, and patient positioning systems that deliver submillimeter repeatability. Software distinctions include delivery control systems versus treatment planning platforms, with planning tools increasingly central to efficiency and plan quality. Finally, service segmentation-covering installation and commissioning, preventive maintenance, corrective maintenance, and training and support-becomes a determinant of clinical uptime and user confidence, with full lifecycle service models proving essential for sustaining complex intracranial programs.

Regional contrasts in clinical adoption, reimbursement drivers and infrastructure investments shaping differentiated deployment strategies across the Americas, EMEA and Asia-Pacific

Regional dynamics influence technology adoption, reimbursement pathways, and the structure of clinical networks that deliver stereotactic intracranial care. In the Americas, a mature ecosystem of research hospitals, insurer reimbursement models that recognize stereotactic radiosurgery efficacy, and strong capital markets support the early adoption of integrated imaging and software-led platforms. Centers of excellence in major metropolitan areas act as referral hubs and training centers, shaping clinical protocols that other institutions emulate, while ambulatory settings increasingly participate in delivering selected procedures under appropriate clinical governance.

Europe, the Middle East and Africa exhibit heterogeneous adoption patterns driven by national regulatory frameworks, public health procurement cycles, and variable access to specialized personnel. Western European centers place a premium on clinical evidence and interoperability with national health records, while certain Middle Eastern health systems pursue rapid modernization through targeted capital investment. In Africa, adoption concentrates in select tertiary centers and research collaborations, with emphasis on durable service agreements. Asia-Pacific demonstrates a dynamic mix of innovation and scale: high-income markets invest in advanced imaging integration and academic partnerships, while emerging markets focus on expanding access through tiered service offerings, training programs, and selective local manufacturing or assembly to manage cost and supply continuity.

Competitive differentiation driven by integrated clinical evidence, modular hardware-software platforms, localized service networks and flexible commercial models to match evolving provider needs

Competitive advantage in this sector increasingly depends on how companies balance product differentiation, clinical evidence generation, and service excellence. Leading suppliers that combine modular hardware with sophisticated treatment planning platforms can offer compelling value propositions by reducing total time in the treatment pathway and enabling a broader set of clinical indications. Strategic collaborations with academic centers and research hospitals accelerate clinical validation and create pathways for guideline inclusion, while partnerships with imaging vendors facilitate tighter integration between treatment planning and intra-procedural imaging.

Service architecture also differentiates firms: those offering comprehensive installation and commissioning services, predictable preventive maintenance schedules, rapid corrective response, and immersive training and support programs find greater acceptance among high-volume centers that cannot tolerate extended downtime. Additionally, supply-chain strategies, such as regional parts depots and local service technicians, reduce time to repair and support tariff mitigation efforts. Finally, companies that adopt flexible commercial models-blending capital purchase, leasing, and outcome-linked agreements-respond more effectively to institutional budget constraints and changing care delivery models.

Practical strategic and operational actions for technology providers and health systems to accelerate safe adoption, optimize lifecycle economics and sustain clinical outcomes

Industry leaders must take deliberate, actionable steps to capture clinical trust while ensuring operational sustainability. Investing in integrated imaging compatibility-supporting both CT- and MRI-based planning workflows-and offering modular collimator options can broaden clinical applicability and reduce site-level customization. Equally important is the prioritization of software improvements that automate routine planning tasks, accelerate quality assurance processes, and surface clinically meaningful plan trade-offs to multidisciplinary teams. Leaders should also formalize partnerships with academic and research institutes to co-develop protocols and publish outcomes that inform payer and guideline decisions.

Operationally, companies should expand regional service footprints, create inventory buffers for high-failure-rate components, and provide robust training programs that certify local clinical and technical staff. Pricing strategies that include flexible financing, pay-per-use pilots, and bundled service offerings can lower the barrier to adoption for ambulatory centers and hospitals with constrained capital. Finally, proactive engagement with regulators and payers to demonstrate clinical value and real-world outcomes will reduce adoption friction and create durable pathways for technology uptake.

Mixed-method research design combining clinician interviews, technical specification audits, regulatory review and supply-chain mapping to ensure robust and actionable insights

This analysis synthesizes primary qualitative inputs and secondary technical review to ensure both empirical rigor and clinical relevance. Primary research consisted of structured interviews with practicing radiation oncologists, neurosurgeons, medical physicists, hospital procurement leaders, and service engineers to capture decision criteria across clinical, technical, and financial dimensions. Secondary research included review of peer-reviewed clinical literature, device regulatory filings, imaging and dosimetry technical notes, and publicly available hospital procurement frameworks to validate technical claims and service models.

Analytical methods emphasized triangulation across sources, mapping component-level supply chains, and scenario analysis for procurement and service outcomes under varying policy and tariff environments. Quality controls included cross-validation of technical specifications with practicing physicists and independent review of clinical workflow assumptions by multidisciplinary clinicians. Limitations center on the rapidly evolving nature of software-enabled features and regional regulatory shifts; where uncertainty exists, the analysis highlights probable directional impacts rather than definitive projections.

Synthesis of clinical, technical and operational priorities highlighting the imperatives that will determine durable adoption and sustained clinical impact

The cumulative assessment points to an inflection where technology capability, service sophistication, and operational resilience converge to determine long-term success. Clinically, systems that offer precise dosimetry, integrated imaging, and streamlined treatment planning address the core needs of neurosurgical and radiation oncology teams treating arteriovenous malformation, primary and metastatic brain tumors, and functional indications such as trigeminal neuralgia. Commercially, the ability to offer durable service agreements, modular hardware options, and software platforms that accelerate throughput creates compelling value propositions for a range of end users from academic institutes to ambulatory surgical centers.

Looking ahead, predictable service delivery, supply-chain transparency, and partnerships that yield clinical evidence will be the most important differentiators. Organizations that align product development with clinician workflow needs and that embed comprehensive training and maintenance into their commercial offerings will reduce barriers to adoption and sustain clinical performance. In short, the market rewards solutions that address both the technical challenge of precise intracranial targeting and the operational demands of delivering high-volume, reliable care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Gamma Beam Stereotactic Radiotherapy System Market, by Component

  • 8.1. Hardware
    • 8.1.1. Collimator System
      • 8.1.1.1. Fixed Collimator
      • 8.1.1.2. Sector Collimator
    • 8.1.2. Imaging System
      • 8.1.2.1. CT Based Imaging
      • 8.1.2.2. MRI Based Imaging
    • 8.1.3. Patient Positioning System
  • 8.2. Software
    • 8.2.1. Delivery Control System
    • 8.2.2. Treatment Planning Platform
  • 8.3. Services
    • 8.3.1. Installation & Commissioning
    • 8.3.2. Preventive Maintenance
    • 8.3.3. Training & Support

9. Gamma Beam Stereotactic Radiotherapy System Market, by Application

  • 9.1. Arteriovenous Malformation
  • 9.2. Brain Tumor
  • 9.3. Metastatic Brain Disease
  • 9.4. Trigeminal Neuralgia

10. Gamma Beam Stereotactic Radiotherapy System Market, by End User

  • 10.1. Academic And Research Institutes
  • 10.2. Ambulatory Surgical Centers
  • 10.3. Cancer Research Institutes
  • 10.4. Hospitals

11. Gamma Beam Stereotactic Radiotherapy System Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Gamma Beam Stereotactic Radiotherapy System Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Gamma Beam Stereotactic Radiotherapy System Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States Gamma Beam Stereotactic Radiotherapy System Market

15. China Gamma Beam Stereotactic Radiotherapy System Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. Accuray Incorporated
  • 16.6. Brainlab AG
  • 16.7. C-Rad AB
  • 16.8. Canon Medical Systems Corporation
  • 16.9. Elekta AB
  • 16.10. GE Healthcare
  • 16.11. Hitachi, Ltd.
  • 16.12. IBA Worldwide
  • 16.13. LinaTech LLC
  • 16.14. Mevion Medical Systems, Inc.
  • 16.15. Mitsubishi Electric Corporation
  • 16.16. Neusoft Medical Systems Co., Ltd.
  • 16.17. Philips Healthcare
  • 16.18. ProTom International, Inc.
  • 16.19. RaySearch Laboratories AB
  • 16.20. Shenzhen Anke High-tech Co., Ltd.
  • 16.21. Shinva Medical Instrument Co., Ltd.
  • 16.22. Sumitomo Heavy Industries, Ltd.
  • 16.23. TopGrade HealthCare Inc.
  • 16.24. Toshiba Corporation
  • 16.25. United Imaging Healthcare Co., Ltd.
  • 16.26. Varian Medical Systems, Inc.
  • 16.27. ViewRay, Inc.
  • 16.28. Wandong Medical Equipment Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY HARDWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY HARDWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY HARDWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COLLIMATOR SYSTEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COLLIMATOR SYSTEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COLLIMATOR SYSTEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COLLIMATOR SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY FIXED COLLIMATOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY FIXED COLLIMATOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY FIXED COLLIMATOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SECTOR COLLIMATOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SECTOR COLLIMATOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SECTOR COLLIMATOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY IMAGING SYSTEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY IMAGING SYSTEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY IMAGING SYSTEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY IMAGING SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY CT BASED IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY CT BASED IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY CT BASED IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY MRI BASED IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY MRI BASED IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY MRI BASED IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY PATIENT POSITIONING SYSTEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY PATIENT POSITIONING SYSTEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY PATIENT POSITIONING SYSTEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY DELIVERY CONTROL SYSTEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY DELIVERY CONTROL SYSTEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY DELIVERY CONTROL SYSTEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY TREATMENT PLANNING PLATFORM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY TREATMENT PLANNING PLATFORM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY TREATMENT PLANNING PLATFORM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY INSTALLATION & COMMISSIONING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY INSTALLATION & COMMISSIONING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY INSTALLATION & COMMISSIONING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY PREVENTIVE MAINTENANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY PREVENTIVE MAINTENANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY PREVENTIVE MAINTENANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY TRAINING & SUPPORT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY TRAINING & SUPPORT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY TRAINING & SUPPORT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY ARTERIOVENOUS MALFORMATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY ARTERIOVENOUS MALFORMATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY ARTERIOVENOUS MALFORMATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY BRAIN TUMOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY BRAIN TUMOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY BRAIN TUMOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY METASTATIC BRAIN DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY METASTATIC BRAIN DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY METASTATIC BRAIN DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY TRIGEMINAL NEURALGIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY TRIGEMINAL NEURALGIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY TRIGEMINAL NEURALGIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COLLIMATOR SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY IMAGING SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COLLIMATOR SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY IMAGING SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COLLIMATOR SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY IMAGING SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COLLIMATOR SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY IMAGING SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COLLIMATOR SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY IMAGING SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COLLIMATOR SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY IMAGING SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COLLIMATOR SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY IMAGING SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COLLIMATOR SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY IMAGING SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COLLIMATOR SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY IMAGING SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. GCC GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GCC GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 164. GCC GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 165. GCC GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COLLIMATOR SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 166. GCC GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY IMAGING SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 167. GCC GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 168. GCC GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 169. GCC GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 170. GCC GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COLLIMATOR SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY IMAGING SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COLLIMATOR SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY IMAGING SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. G7 GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. G7 GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 191. G7 GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 192. G7 GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COLLIMATOR SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 193. G7 GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY IMAGING SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 194. G7 GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 195. G7 GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 196. G7 GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 197. G7 GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. NATO GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. NATO GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 200. NATO GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 201. NATO GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COLLIMATOR SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 202. NATO GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY IMAGING SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 203. NATO GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 204. NATO GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 205. NATO GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 206. NATO GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COLLIMATOR SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY IMAGING SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COLLIMATOR SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY IMAGING SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)